Safety Profile and Tolerability

For a first-in-class therapy delivered intrathecally to children with a complex and treatment-burdened disease, the safety profile of zorevunersen across 81 patients and multi-year follow-up is an important part of the clinical story. Understanding what was observed -- and what was not -- shapes how clinicians and families can approach treatment decisions as zorevunersen moves toward broader use.

Dr. Schreiber opens by framing the safety assessment in the context of what matters to patients. Data from epilepsy and developmental and epileptic encephalopathies increasingly shows that adverse events from antiseizure medications have a significant impact on quality of life -- sedation, cognitive blunting, behavioral side effects -- and that families weigh these costs carefully. Against that backdrop, the most commonly observed adverse events with zorevunersen were procedure-related: post-lumbar-puncture syndrome, headache, nausea, and effects associated with anesthesia used to facilitate the intrathecal administration in children. The other notable finding was elevated CSF protein, which is commonly seen with intrathecal ASO therapies. These elevations were asymptomatic -- patients experienced no persistent headache or other clinical symptoms attributable to the protein elevation -- and were monitored carefully. Dosing pauses occurred in rare instances when protein levels exceeded 250, but such cases were uncommon.

Dr. Wirrell adds important context: no cases of hydrocephalus were observed across 81 patients, which she identifies as a reassuring signal given that CSF protein elevation in other intrathecal therapies can raise this concern. She also notes that the protein elevations were not continuously progressive; they rose, stabilized, and in many cases declined, rather than accumulating indefinitely.

Dr. Wheless articulates what he describes as a qualitatively different safety conversation. Clinicians accustomed to discussing sedation, dizziness, drug interactions, and behavioral effects with families of Dravet patients will find the zorevunersen safety discussion largely free of those concerns. The therapy does not produce the typical drug-related side effects, does not interact with other medications because it is delivered intrathecally, and does not impair alertness or cognition. The safety profile is dominated by what are essentially laboratory findings -- CSF protein elevations that families are often not even aware of -- and by the logistical considerations of the administration route itself. He notes that for children, the intrathecal procedure is well tolerated when mild sedation is used, and the overall picture is one where almost every patient chose to continue into the open-label extension. The number of discontinuations due to adverse events was very small, which Dr. Wheless describes as a meaningful signal in a population that has lived with the real-world side effects of multiple antiseizure medications and is well positioned to compare.